Secondary primary malignancies ‘rare’ after CAR T-cell immunotherapy
A US study shows a projected five-year cumulative incidence of 15.2% for solid and 2.3% for haematological malignancies in treated patients.
The incidence of secondary primary malignancy after anti-CD19 chimeric antigen receptor T-cell immunotherapy is very low, according to a study in Nature Medicine.
US researchers describe a case of T-cell lymphoma occurring three months after chimeric antigen receptor (CAR) T-cell immunotherapy for non-Hodgkin B-cell lymphoma, which was diagnosed from a thoracic lymph node identified during lung cancer surgery.
To assess the overall risk of secondary primary malignancy, 449 patients treated at the University of Pennsylvania were reviewed.
The researchers found that the CAR transgene was low, while the T-cell lymphoma exhibited CD8+ cytotoxic phenotype and a JAK3 variant.
